Drug Trial Radar · NCT01712490
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,334
Actual
Start
Nov 9, 2012
Primary completion
Apr 20, 2017
Study completion Feb 2, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Seagen Inc.
- First posted
- Oct 23, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin \[Adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Conditions
- Hodgkin Lymphoma
Interventions
brentuximab vedotinDrug
Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
doxorubicinDrug
Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
bleomycinDrug
Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
vinblastineDrug
Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
dacarbazineDrug
Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)Time frame: Baseline until PD or death or receipt of any subsequent anticancer therapy for HL after completion of frontline therapy (approximately up to 4 years)
Locations
215 sites in 21 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Gilbert, Arizona
Site not named
Tucson, Arizona
Site not named
Burbank, California
Site not named
Duarte, California
Site not named
Fresno, California
Site not named
Fullerton, California
Site not named
La Jolla, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
San Luis Obispo, California
Site not named
Santa Barbara, California
Site not named
Santa Monica, California
Site not named
Stanford, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Lonetree, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Fort Myers, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Lawrenceville, Georgia
Site not named
Chicago, Illinois
Site not named
Maywood, Illinois
Site not named
Niles, Illinois
Site not named
Zion, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Goshen, Indiana
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Fairway, Kansas
Site not named
Baltimore, Maryland
Site not named
Bethesda, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Rochester, Minnesota
Showing 40 of 215 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.